The potential role of platelet microparticles in atherosclerosis

Summary

The release of microvesicles (‘platelet microparticles’, PMPs) by activated platelets has been shown to be an integral part of the thrombotic process. PMPs are believed to mediate many biological processes as they possess various platelet membrane proteins and bioactive lipids. Of note, there is a growing body of evidence that PMPs are involved in all stages in the pathobiology of atherosclerosis. In addition to their role in thrombosis, PMPs may also have a pro-inflammatory effect, which promotes the development of atherosclerosis. Also, bioactive lipids in PMPs have been shown to have important effects on angiogenesis. This review summarises the various studies on the possible role of PMPs in the progression of atherosclerosis.

Keywords

Platelets - platelet microparticles - thrombosis - atherosclerosis

• References

• 1 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of the atherosclerotic lesions formation.. J Exp Med 2002; 196: 887-96.
• 2 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.. Nat Med 2003; 9: 61-7.
• 3 Siljander P, Carpen O, Lassila R. Platelet derived microparticles associate with fibrin during thombosis.. Blood 1996; 87: 4651-63.
• 4 Lee YJ, Jy W, Horstman LL. et al. Elevated platelet microparticles in transient ischaemic attacks, lacunar infarcts, and multiinfarct dementias.. Thromb Res 1993; 72: 295-304.
• 5 Nomura S, Uehata S, Saito S. et al. Enzyme immunoassay detection of platelet derived microparticles and RANTES in acute coronary syndromes.. Thromb Haemost 2003; 89: 506-12.
• 6 Zeiger F, Stephan S, Hoheisel G. et al. P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease.. Blood Coagul Fibrinolysis 2000; 11: 723-8.
• 7 Tan KT, Tayebjee MH, Lynd C. et al. Platelet microparticles and soluble P-selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers.. Ann Med 2005; 37: 61-6.
• 8 Bernal-Mizrachi L, Jy W, Jimenez JJ. et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes.. Am Heart J 2003; 145: 962-70.
• 9 Tan KT, Tayebjee MH, MacFadyen R. et al. Elevated platelet microparticles in stable coronary disease are unrelated to disease severity or to indices of inflammation.. Platelets. 2005 (in press).
• 10 Shouzu A, Nomura S, Omoto S. et al. Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus.. Clin Appl Thromb Hemost 2004; 10: 167-73.
• 11 Preston RA, Jy W, Jimenez JJ. et al. Effects of severe hypertension on endothelial and platelet microparticles.. Hypertension 2003; 41: 211-7.
• 12 Heijnen HF, Schiel AE, Fijnheer R. et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.. Blood 1999; 94: 3791-99.
• 13 Yano Y, Kambayashi J, Shiba E. et al. The role of protein phosphorylation and cytoskeletal reorganisation in microparticle formation from the platelet plasma membrane.. Biochem J 1994; 299: 303-8.
• 14 Tans G, Rosing J, Thomassen MC. et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet derived microparticles.. Blood 1991; 77: 2641-8.
• 15 Barry OP, Pratico D, Savani RC. et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles.. J Clin Invest 1998; 102: 136-44.
• 16 English D, Garcia JG, Brindley DN. Platelet-released phospholipids link haemostasis and angiogenesis.. Cardiovasc Res 2001; 49: 588-99.
• 17 Muller I, Klocke A, Alex M. et al. Intravascular tissue factor initiates coagulation via ciculating microvesicles and platelets.. FASEB J 2003; 17: 476-8.
• 18 Chou J, Mackman N, Merrill-Skoloff G. et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.. Blood 2004; 104: 3190-97.
• 19 Day SM, Reeve JL, Pedersen B. et al. Macrovascular thrombosis is driven by tissue factor derived primarily from blood vessel wall.. Blood 2005; 105: 192-8.
• 20 Biro E, Sturk-Maquelin KN, Vogel GM. et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.. J Thromb Haemost 2003; 1: 2561-8.
• 21 Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids.. Biochim Biophys Acta 2004; 1636: 119-28.
• 22 Chang CP, Zhao J, Wiedmer T, Sims PJ. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine.. J Biol Chem 1993; 268: 71711-8.
• 23 Munnix IC, Harmsma M, Giddings JC. et al. Storemediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients.. Thromb Haemost 2003; 89: 687-95.
• 24 Castaman G, Yu-Feng L, Battistin E. et al. Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation.. Br J Haematol 1997; 96: 458-63.
• 25 Podor TJ, Singh D, Chindemi P. et al. Vimentin exposed on activated platelets and platelet microparticles localises vitronectin and plasminogen activator inhibitor complexes on their surface.. J Biol Chem 2002; 277: 7529-39.
• 26 Horrevoets AJ. Plasminogen activator inhibitor 1: in vitro activities and clinical relevance.. Br J Haematol 2004; 125: 12-23.
• 27 Booth NA, Simpson AJ, Croll A. et al. Plasminogen activator inhibitor in plasma and platelets.. Br J Haematol 1988; 70: 327-33.
• 28 Salonen EM, Vaheri A, Pollanen J. et al. Interaction of plasminogen activator inhibitor with vitronectin.. J Biol Chem 1989; 264: 6339-43.
• 29 Miles LA, Ginsberg MH, White JG. et al. Plasminogen interacts with human platelets through two distinct mechanisms.. J Clin Invest 1986; 77: 2001-9.
• 30 Merten M, Pakala R, Thiagarajan P. et al. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism.. Circulation 1999; 99: 2577-82.
• 31 Gawaz M, Neumann FJ, Dickfield T. et al. Vitronectin receptor mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction.. Circulation 1997; 96: 1809-18.
• 32 Barry OP, Pratico D, Lawson JA. et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles.. J Clin Invest 1997; 99: 2118-27.
• 33 Tan KT, Lip GY. Platelets, atherosclerosis and the endothelium: new therapeutic targets?. Expert Opin Investig Drugs 2003; 12: 1765-76.
• 34 Ross R. Atherosclerosis- an inflammatory disease.. N Engl J Med 1999; 340: 115-26.
• 35 Nomura S, Tandon NN, Nakamura T. et al. Highshear stress induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells.. Atherosclerosis 2001; 158: 277-87.
• 36 Weber A, Koppen HO, Schror K. Platelet-derived microparticles stimulate coronary artery smooth muscle mitogenesis by a PDGF-independent mechanism.. Thromb Res 2000; 98: 461-6.
• 37 Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development.. Blood 2003; 101: 2661-6.
• 38 Forlow SB, McEver RP, Nollert MU. Leukocyteleukocyte interactions mediated by platelet microparticles under flow.. Blood 2000; 9: 1317-23.
• 39 Jy W, Mao WW, Horstman L. et al. Platelet microparticles bind, activate, and aggregate neutrophils in vitro.. Blood Cells Mol Dis 1995; 21: 217-31.
• 40 Tan KT, Lip GY, Blann AD. Post-stroke inflammatory response: effects of stroke evolution and outcome.. Curr Atheroscler Rep 2003; 5: 245-51.
• 41 Kim HK, Song KS, Chung JH. et al. Platelet microparticles induce angiogenesis in vitro.. Br J Haematol 2004; 124: 376-84.
• 42 O’Brien K, Allen M, MacDonald T. et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: Implications for the mode of progression of advanced coronary atherosclerosis.. J Clin Invest 1993; 92: 945-51.
• 43 Moulton KS, Heller E, Konerding MA. et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularisation and plaque.. Circulation 1999; 99: 1726-32.